{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:48:12Z","timestamp":1791244092332,"version":"4.1.0"},"reference-count":78,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008568","name":"norske kvinners sanitetsforening","doi-asserted-by":"publisher","award":["H2\/2018"],"award-info":[{"award-number":["H2\/2018"]}],"id":[{"id":"10.13039\/501100008568","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the norwegian council on cardiovascular disease"},{"name":"the odd-fellow foundation"},{"DOI":"10.13039\/501100011076","name":"simon fougner hartmanns familiefond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011076","id-type":"DOI","asserted-by":"publisher"}]},{"name":"abbvie"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The complement system plays an important role in pathophysiology of cardiovascular disease (CVD), and might be involved in accelerated atherogenesis in rheumatoid arthritis (RA). The role of complement activation in response to treatment, and in development of premature CVD in RA, is limited. Therefore, we examined the effects of methotrexate (MTX) and tumor necrosis factor inhibitors (TNFi) on complement activation using soluble terminal complement complex (TCC) levels in RA; and assessed associations between TCC and inflammatory and cardiovascular biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We assessed 64 RA patients starting with MTX monotherapy (n = 34) or TNFi with or without MTX co-medication (TNFi\u00b1MTX, n = 30). ELISA was used to measure TCC in EDTA plasma. The patients were examined at baseline, after 6 weeks and 6 months of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median TCC was 1.10 CAU\/mL, and 57 (89%) patients had TCC above the estimated upper reference limit (&lt;0.70). Compared to baseline, TCC levels were significantly lower at 6-week visit (0.85 CAU\/mL, p&lt;0.0001), without significant differences between the two treatment regimens. Notably, sustained reduction in TCC was only achieved after 6 months on TNFi\u00b1MTX (0.80 CAU\/mL, p = 0.006). Reductions in TCC after treatment were related to decreased C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and interleukin 6, and increased levels of total, high and low-density lipoprotein cholesterol. Similarly, baseline TCC was significantly related to baseline CRP, ESR and interleukin 6. Patients with endothelial dysfunction had higher baseline TCC than those without (median 1.4 versus 1.0 CAU\/mL, p = 0.023).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with active RA had elevated TCC, indicating increased complement activation. TCC decreased with antirheumatic treatment already after 6 weeks. However, only treatment with TNFi\u00b1MTX led to sustained reduction in TCC during the 6-month follow-up period. RA patients with endothelial dysfunction had higher baseline TCC compared to those without, possibly reflecting involvement of complement in the atherosclerotic process in RA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0264628","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T14:00:04Z","timestamp":1645797604000},"page":"e0264628","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Antirheumatic therapy is associated with reduced complement activation in rheumatoid arthritis"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2597-4031","authenticated-orcid":true,"given":"Thao H. P.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Hokstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Wang","family":"Fagerland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom Eirik","family":"Mollnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Hollan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Feinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnbj\u00f8rg","family":"Hjeltnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gro \u00d8.","family":"Eilertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Mikkelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Agewall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"pone.0264628.ref001","doi-asserted-by":"crossref","first-page":"k1036","DOI":"10.1136\/bmj.k1036","article-title":"Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications","volume":"361","author":"BR England","year":"2018","journal-title":"BMJ"},{"key":"pone.0264628.ref002","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrrheum.2015.112","article-title":"Cardiovascular comorbidity in rheumatic diseases.","volume":"11","author":"MT Nurmohamed","year":"2015","journal-title":"Nat. Rev. Rheumatol"},{"issue":"9","key":"pone.0264628.ref003","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","article-title":"Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"71","author":"JA Avina-Zubieta","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"pone.0264628.ref004","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.amjmed.2008.06.014","article-title":"Role of Inflammation in Atherosclerosis Associated with Rheumatoid Arthritis","volume":"121","author":"P. Libby","year":"2008","journal-title":"Am. J. Med"},{"issue":"12","key":"pone.0264628.ref005","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1042\/CS20180306","article-title":"Atherosclerosis and inflammation: overview and updates","volume":"132","author":"GR Geovanini","year":"2018","journal-title":"Clin. Sci"},{"issue":"1","key":"pone.0264628.ref006","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2017-211735","article-title":"Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis","volume":"77","author":"CS Crowson","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"pone.0264628.ref007","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/ehjcvp\/pvz033","article-title":"Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology","volume":"6","author":"I Hollan","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"7","key":"pone.0264628.ref008","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nrrheum.2015.40","article-title":"Atherosclerosis in rheumatoid arthritis: is it all about inflammation?","volume":"11","author":"S Skeoch","year":"2015","journal-title":"Nat Rev Rheumatol."},{"key":"pone.0264628.ref009","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41584-018-0022-8","article-title":"Microvascular endothelial dysfunction in rheumatoid arthritis.","volume":"14","author":"R Bordy","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"pone.0264628.ref010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"JR Dunkelberger","year":"2010","journal-title":"Cell Research"},{"issue":"8","key":"pone.0264628.ref011","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.4049\/jimmunol.1203487","article-title":"Complement in immune and inflammatory disorders: pathophysiological mechanisms","volume":"190","author":"D Ricklin","year":"2013","journal-title":"J Immunol"},{"issue":"1","key":"pone.0264628.ref012","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3390\/cells10010148","article-title":"Complement as a Therapeutic Target in Systemic Autoimmune Diseases.","volume":"10","author":"M Galindo-Izquierdo","year":"2021","journal-title":"Cells"},{"key":"pone.0264628.ref013","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3389\/fimmu.2018.01057","article-title":"Complement in the Initiation and Evolution of Rheumatoid Arthritis.","volume":"9","author":"M Holers","year":"2018","journal-title":"Front. Immunol"},{"issue":"4","key":"pone.0264628.ref014","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/art.10183","article-title":"Local Production of Complement Proteins in Rheumatoid Arthritis Synovium","volume":"46","author":"E Neumann","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"12","key":"pone.0264628.ref015","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/art.1780341209","article-title":"Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis","volume":"34","author":"JP Brodeur","year":"1991","journal-title":"Arthritis Rheum"},{"issue":"12","key":"pone.0264628.ref016","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1136\/ard.55.12.888","article-title":"Complement in acute and chronic arthritides: assessment of C3c, C9, and protectin (CD59) in synovial membrane.","volume":"55","author":"YT Konttinen","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"pone.0264628.ref017","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.molimm.2019.05.012","article-title":"Complement and its Environmental Determinants in the Progression of Human Rheumatoid Arthritis","volume":"112","author":"EA Bemis","year":"2019","journal-title":"Mol. Immunol"},{"key":"pone.0264628.ref018","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/rheumatology\/ken495","article-title":"The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis.","volume":"48","author":"F Corallini","year":"2009","journal-title":"Rheumatology"},{"issue":"3","key":"pone.0264628.ref019","first-page":"473","article-title":"Measurement of terminal complement complexes in rheumatoid arthritis","volume":"73","author":"B. P. Morgan","year":"1988","journal-title":"Clin. Exp. Immunol"},{"issue":"11","key":"pone.0264628.ref020","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/art.1780291108","article-title":"Complement activation in synovial fluid and tissue from patients with juvenile rheumatoid arthritis","volume":"29","author":"TE Mollnes","year":"1986","journal-title":"Arthritis Rheum"},{"issue":"6","key":"pone.0264628.ref021","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/art.1780290603","article-title":"Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex","volume":"29","author":"TE Mollnes","year":"1986","journal-title":"Arthritis Rheum"},{"issue":"2","key":"pone.0264628.ref022","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.molimm.2014.06.036","article-title":"A vital role for complement in heart disease","volume":"61","author":"KT Lappeg\u00e5rd","year":"2014","journal-title":"Mol Immunol"},{"issue":"1","key":"pone.0264628.ref023","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri3345","article-title":"Thrombosis as an intravascular effector of innate immunity","volume":"13","author":"B Engelmann","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"pone.0264628.ref024","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.atherosclerosis.2015.05.038","article-title":"The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis","volume":"241","author":"A Hovland","year":"2015","journal-title":"Atherosclerosis"},{"key":"pone.0264628.ref025","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ni.2001","article-title":"The immune system in atherosclerosis","volume":"12","author":"G Hansson","year":"2011","journal-title":"Nat Immunol"},{"issue":"11","key":"pone.0264628.ref026","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/nm.2538","article-title":"Atherosclerosis: current pathogenesis and therapeutic options","volume":"17","author":"C Weber","year":"2011","journal-title":"Nat Med"},{"issue":"1","key":"pone.0264628.ref027","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4049\/jimmunol.1403044","article-title":"Reconstituted High-Density Lipoprotein Attenuates Cholesterol Crystal-Induced Inflammatory Responses by Reducing Complement Activation","volume":"195","author":"N Niyonzima","year":"2015","journal-title":"J Immunol"},{"issue":"3","key":"pone.0264628.ref028","doi-asserted-by":"crossref","first-page":"e0174577","DOI":"10.1371\/journal.pone.0174577","article-title":"Plasma complement and vascular complement deposition in patients with coronary artery disease with and without inflammatory rheumatic diseases","volume":"2","author":"KJ Shields","year":"2017","journal-title":"PLoS ONE"},{"issue":"3","key":"pone.0264628.ref029","first-page":"415","article-title":"Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-\u03b1-inhibitor.","volume":"31","author":"G Hjeltnes","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"pone.0264628.ref030","doi-asserted-by":"crossref","first-page":"e0169830","DOI":"10.1371\/journal.pone.0169830","article-title":"Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.","volume":"12","author":"G Deyab","journal-title":"PLoS ONE"},{"issue":"6","key":"pone.0264628.ref031","doi-asserted-by":"crossref","first-page":"e0253793","DOI":"10.1371\/journal.pone.0253793","article-title":"Antirheumatic therapy is not associated with changes in circulating N-terminal pro-brain natriuretic peptide levels in patients with autoimmune arthritis","volume":"16","author":"THP Nguyen","year":"2021","journal-title":"PLoS ONE"},{"issue":"3","key":"pone.0264628.ref032","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.","volume":"31","author":"FC Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"issue":"6","key":"pone.0264628.ref033","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.","volume":"79","author":"JS Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"pone.0264628.ref034","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0735-1097(03)00329-2","article-title":"Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease","volume":"41","author":"PO Bonetti","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"pone.0264628.ref035","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1161\/01.CIR.103.16.2084","article-title":"Peripheral arterial responses to treadmill exercise among healthy subjects and atherosclerotic patients","volume":"103","author":"A Rozanski","year":"2001","journal-title":"Circulation"},{"key":"pone.0264628.ref036","unstructured":"https:\/\/www.itamar-medical.com\/pat-technology-peripheral-arterial-tone\/."},{"issue":"5","key":"pone.0264628.ref037","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1161\/HYPERTENSIONAHA.118.11554","article-title":"Physiological Diagnosis Criteria for Vascular Failure Committee.Physiological Diagnostic Criteria for Vascular Failure","volume":"72","author":"A Tanaka","year":"2018","journal-title":"Hypertension"},{"issue":"11","key":"pone.0264628.ref038","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.jacc.2004.08.062","article-title":"Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia","volume":"44","author":"PO Bonetti","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"pone.0264628.ref039","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.molimm.2013.05.221","article-title":"An international serum standard for application in assays to detect human complement activation products","volume":"56","author":"G Bergseth","year":"2013","journal-title":"Mol Immunol"},{"issue":"7","key":"pone.0264628.ref040","doi-asserted-by":"crossref","first-page":"e0220079","DOI":"10.1371\/journal.pone.0220079","article-title":"Tumor necrosis factor inhibitors are associated with reduced complement activation in spondylarthropathies: An observational study","volume":"14","author":"I Hokstad","year":"2019","journal-title":"PLoS ONE"},{"issue":"10","key":"pone.0264628.ref041","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.autrev.2011.04.012","article-title":"Role of the complement system in rheumatoid arthritis and psoriatic arthritis: Relationship with anti-TNF inhibitors","volume":"10","author":"E Ballanti","year":"2011","journal-title":"Autoimmun. Rev"},{"key":"pone.0264628.ref042","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/ard.2004.029124","article-title":"Infliximab treatment reduces complement activation in patients with rheumatoid arthritis","volume":"64","author":"A Familian","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"pone.0264628.ref043","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/039463201102400209","article-title":"Complement system and rheumatoid arthritis: relationships with autobodies, serological, clinic features and anti-TNF treatment.","volume":"24","author":"G Di Muzio","year":"2011","journal-title":"Int J Immunopathol Pharmacol"},{"key":"pone.0264628.ref044","first-page":"333","article-title":"The complement system in liver diseases","volume":"3","author":"X Qin","year":"2006","journal-title":"Cell Mol Immunol"},{"key":"pone.0264628.ref045","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/cmi.2015.97","article-title":"Hepatocytes: a key cell type for innate immunity","volume":"13","author":"Z Zhou","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"pone.0264628.ref046","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF02592409","article-title":"Effect of cytokines on the secretion of the fifth and eighth complement components by HepG2 cells","volume":"24","author":"S Perissutti","year":"1994","journal-title":"Int J Clin Lab Res"},{"key":"pone.0264628.ref047","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1172\/JCI112721","article-title":"Cachectin\/tumor necrosis factor regulates hepatic acute-phase gene expression","volume":"78","author":"DH Perlmutter","year":"1986","journal-title":"J Clin Invest"},{"issue":"23","key":"pone.0264628.ref048","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The Pathogenesis of Rheumatoid Arthritis","volume":"365","author":"I McInnes","year":"2011","journal-title":"N Engl J Med"},{"key":"pone.0264628.ref049","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1749-6632.1982.tb22140.x","article-title":"Complement activation by C-reactive protein complexes","volume":"389","author":"JE Volanakis","year":"1982","journal-title":"Ann N Y Acad Sci"},{"key":"pone.0264628.ref050","first-page":"293","article-title":"Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein","volume":"48","author":"ETH Molenaar","year":"2009","journal-title":"Rheumatol"},{"issue":"1","key":"pone.0264628.ref051","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.semarthrit.2020.11.005","article-title":"C-reactive protein and implications in rheumatoid arthritis and associated comorbidities","volume":"51","author":"JE Pope","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"pone.0264628.ref052","doi-asserted-by":"crossref","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in Inflammation, Immunity, and Disease.","volume":"6","author":"T Tanka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"9","key":"pone.0264628.ref053","doi-asserted-by":"crossref","first-page":"e0162316","DOI":"10.1371\/journal.pone.0162316","article-title":"Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study.","volume":"11","author":"GP Eng","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"pone.0264628.ref054","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1373\/clinchem.2008.119214","article-title":"C-Reactive Protein: Eighty Years from Discovery to Emergence as a Major Risk Marker for Cardiovascular Disease","volume":"55","author":"PM Ridker","year":"2009","journal-title":"Clin Chem"},{"issue":"6","key":"pone.0264628.ref055","first-page":"S76","article-title":"Methotrexate in psoriatic arthritis","volume":"20","author":"M Cutolo","year":"2002","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"pone.0264628.ref056","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/toxsci\/kfm067","article-title":"The Contribution of Methotrexate Exposure and Host Factors on Transcriptional Variance in Human Liver","volume":"97","author":"GS Belinsky","year":"2007","journal-title":"Toxicol Sci"},{"issue":"9","key":"pone.0264628.ref057","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/ATVBAHA.108.179705","article-title":"History of Discovery: Inflammation in Atherosclerosis","volume":"32","author":"P. Libby","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"pone.0264628.ref058","first-page":"389","article-title":"Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities","volume":"16","author":"M B\u00e4ck","year":"2019","journal-title":"Nat. Rev. Cardiol"},{"issue":"9","key":"pone.0264628.ref059","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1242\/jcs.179291","article-title":"Complement-mediated \u2018bystander\u2019 damage initiates host NLRP3 inflammasome activation.","volume":"129","author":"R Suresh","year":"2016","journal-title":"J Cell Sci"},{"issue":"15","key":"pone.0264628.ref060","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1096\/fj.00-0468fje","article-title":"The terminal complement complex C5b-9 stimulates interleukin-6 production in human smooth-muscle cells through activation of transcription factors NF-\u03baB and AP-1","volume":"14","author":"C Viedt","year":"2000","journal-title":"FASEB J"},{"issue":"2","key":"pone.0264628.ref061","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijcard.2014.04.057","article-title":"Complement activation products C5a and sC5b-9 are associated with low-grade inflammation and endothelial dysfunction, but not with atherosclerosis in a cross-sectional analysis: The CODAM study.","volume":"174","author":"E Hertle","year":"2014","journal-title":"Int. J. Cardiol"},{"key":"pone.0264628.ref062","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/rheumatology\/ken495","article-title":"The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis.","volume":"48","author":"F Corallini","year":"2009","journal-title":"Rheumatology"},{"issue":"3","key":"pone.0264628.ref063","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3109\/03009742.2012.656698","article-title":"Endothelial function improves within 6 weeks of treatment with methotrexate or methotrexate in combination with a TNF-\u03b1 inhibitor in rheumatoid arthritis patients","volume":"41","author":"G Hjeltnes","year":"2012","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"pone.0264628.ref064","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s13075-017-1439-1","article-title":"Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis.","volume":"19","author":"G Deyab","year":"2017","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"pone.0264628.ref065","first-page":"7","article-title":"Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension.","volume":"23","author":"J Deanfield","year":"2005","journal-title":"J Hypertens"},{"issue":"2","key":"pone.0264628.ref066","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0735-1097(01)01746-6","article-title":"Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force","volume":"39","author":"MC Corretti","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"pone.0264628.ref067","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/cbf.1745","article-title":"Comparing EndoPAT and BIOPAC measurement of vascular responses to mental stress","volume":"29","author":"EA Martin","year":"2011","journal-title":"Cell Biochem Funct"},{"issue":"1","key":"pone.0264628.ref068","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phanu.2013.07.001","article-title":"Acute cigarette smoking impairs microvascular function in young moderate smokers: A potential model for studying vasoactive properties of food bioactives.","volume":"2","author":"CD Bo\u2019","year":"2014","journal-title":"PharmaNutrition"},{"issue":"7","key":"pone.0264628.ref069","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1016\/S0735-1097(00)00980-3","article-title":"Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: an effect prevented by vitamins C and E","volume":"36","author":"LM Title","year":"2000","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"pone.0264628.ref070","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s102380200004","article-title":"Relationship between serum complement and different lipid disorders","volume":"2","author":"AL Pasqui","year":"2002","journal-title":"Clin Exp Med"},{"key":"pone.0264628.ref071","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/annrheumdis-2011-200493","article-title":"Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis","volume":"71","author":"C Charles-Schoeman","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"pone.0264628.ref072","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/art.37916","article-title":"Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial","volume":"65","author":"I Navarro-Mill\u00e1n","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"3","key":"pone.0264628.ref073","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/BOR.0000000000000378","article-title":"Lipids and lipid changes with synthetic and biologic disease modifying antirheumatic drug therapy in rheumatoid arthritis: implications for cardiovascular risk.","volume":"29","author":"E Myasoedova","year":"2017","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"pone.0264628.ref074","doi-asserted-by":"crossref","first-page":"e001588","DOI":"10.1161\/JAHA.114.001588","article-title":"The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis","volume":"4","author":"KP Liao","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"pone.0264628.ref075","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.atherosclerosis.2016.11.015","article-title":"High density lipoproteins are modulators of protease activity: Implications in inflammation, complement activation, and atherothrombosis","volume":"259","author":"SM Gordon","year":"2017","journal-title":"Atherosclerosis"},{"key":"pone.0264628.ref076","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.freeradbiomed.2014.01.015","article-title":"Nrf2 Signaling Modulates Cigarette Smoke Induced Complement Activation in Retinal Pigmented Epithelial Cells.","volume":"70","author":"L Wang","year":"2014","journal-title":"Radic Biol Med"},{"issue":"4","key":"pone.0264628.ref077","doi-asserted-by":"crossref","first-page":"L254","DOI":"10.1152\/ajplung.1991.260.4.L254","article-title":"Complement activation by cigarette smoke","volume":"260","author":"RA Robbins","year":"1991","journal-title":"Am J Physiol Cell Mol Physiol"},{"issue":"2","key":"pone.0264628.ref078","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.thromres.2007.11.005","article-title":"Regulated complement deposition on the surface of human endothelial cells: effect of tobacco smoke and shear stress","volume":"122","author":"W Yin","year":"2008","journal-title":"Thromb Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0264628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T05:05:44Z","timestamp":1726722344000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0264628"}},"subtitle":[],"editor":[{"given":"Gianluigi","family":"Savarese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":78,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0264628","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,25]]}}}